Changes in left ventricular (LV) diastolic filling anticipate diastolic heart failure and are frequently detected in patients with hypertension or diabetes. We tested the hypothesis that increased fasting and postload glucose levels are associated with diastolic dysfunction as assessed by tissue Doppler imaging (TDI) in hypertensive patients.
Recent evidence indicates that diastolic heart failure is associated with a mortality rate similar to systolic heart failure 1 and is anticipated by changes in left ventricular (LV) diastolic filling properties that reflect stiffening of the ventricular wall. These changes in diastolic function have been shown to predict death, 2 even in the absence of clinically overt heart failure. Diastolic dysfunction can be detected in a variety of conditions, including aging, hypertension, LV hypertrophy, myocardial ischemia, and diabetes mellitus. 3 A significant association of abnormal LV structure 4 and diastolic filling 5 with diabetes and impaired glucose metabolism has been reported in previous studies, and in a large randomized trial conducted on high cardiovascular risk patients, fasting plasma glucose was shown to be a prognostic factor for heart failure, independent of diabetes. 6 Some studies, however, have not confirmed the association between abnormalities of glucose metabolism and LV diastolic dysfunction, 7, 8 and the relative contributions to this association of fasting and postprandial plasma glucose levels or decreased insulin sensitivity are still debated. Availability of pulsed tissue Doppler imaging (TDI) to the study of transmitral flow permits more sensitive and reproducible 9 detection of impaired LV diastolic function, thereby offering the opportunity for further investigation of its relationship with abnormal glucose metabolism. Because of the relevance of the combined effects of high blood pressure and impaired glucose metabolism on LV function, we have tested the hypothesis that elevated fasting and post-oral load glucose levels contribute to LV diastolic dysfunction as detected by TDI in nondiabetic hypertensive patients.
METHODS

Patients
In a cross-sectional study, we included 104 essential hypertensive patients (58 men, 46 women; aged 49 ± 14 years) who were consecutively referred to the Hypertension Unit of our Downloaded from https://academic.oup.com/ajh/article-abstract/26/11/1353/153652 by guest on 15 February 2019 clinic. Blood pressure was measured by an automated device (Omron M6; OMRON Healthcare, Kyoto, Japan) after each subject had been supine for 15 minutes, and the average of 5 readings obtained in 5 minutes was recorded. Increased blood pressure (systolic blood pressure ≥140 mm Hg and/ or diastolic blood pressure ≥90 mm Hg) was detected at least twice on 2 different occasions and subsequently confirmed on at least 2 more visits during the 4 weeks that followed. The patients seen at our clinic include individuals with all grades of hypertension who live in the northeast of Italy and are representative of the hypertensive population of this geographical area. 10 Exclusion criteria were aged <18 or >80 years; pregnancy; body mass index (BMI) of ≥35; diabetes mellitus; ischemic heart, cardiac valve, or other heart diseases; carotid artery and peripheral vascular disease; renal failure with creatinine clearance of <60 ml/min/1.73 m 2 body surface area; and presence of other diseases or treatments that might interfere with glucose metabolism. All patients had normal exercise tolerance and no evidence of ischemic heart disease on electrocardiogram (ECG) and echocardiography. Thirty-four patients (33%) had never been treated with antihypertensive drugs. Of the remaining patients, 36 (35%) were on angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, 34 (33%) were on calcium-channel blockers, 24 (23%) were on beta-blockers, 24 (23%) were on diuretics, and 2 (2%) were on alpha-blockers. Patients who were treated with antihypertensive drugs were withdrawn from treatment for a minimum of 2 weeks before diagnostic assessment and measurement of metabolic parameters. Patients taking ≥2 antihypertensive drugs were admitted to the hospital, and in those with blood pressure persistently >180/110 mm Hg (n = 6), alpha-blockers (n = 6) and/or calcium-channel blockers (n = 2) were given. Before the study, patients ate a standard diet for 7 days to maintain a sodium intake of 100-150 mmol/day that was controlled with measurement of sodium excretion in 24-hour urine collections. Secondary forms of hypertension were excluded by exhaustive laboratory testing, as described previously. 11 In all patients, a 12-lead standard ECG was done, and it was analyzed for criteria of LV hypertrophy and strain pattern of the S-T segment. 12 A venous blood sample was drawn without venous stasis between 8:00 and 9:00 am after an overnight fast. Plasma glucose was assayed by the glucose-oxidase method. Plasma insulin and C-peptide levels were measured by radioimmunoassay. The Homeostatic Model Assessment (HOMA) index was calculated as an index of insulin sensitivity from fasting plasma glucose (mmol/L) and insulin (µU/mL) using the formula: [(glucose × insulin)/22.5].
In all patients, an oral glucose tolerance test was performed with a standard load (75 g of glucose) and measurement of plasma glucose and insulin at 30, 60, 90, 120, and 180 minutes. The area under the curve for glucose (G-AUC) and insulin (I-AUC) response to the glucose load was calculated by the trapezoidal rule. 13 According to the American Diabetes Association guidelines, 14 patients were classified as having impaired fasting glucose (IFG) when fasting plasma glucose was 100-125 mg/dL and impaired glucose tolerance (IGT) when plasma glucose level at 120 minutes of the oral glucose load was between 140-199 mg/dL. The study was approved by the local institutional review board, and informed consent was obtained from all patients.
Cardiac ultrasound examination
All cardiac ultrasound examinations were performed by the same trained investigator, who was unaware of the clinical and biochemical characteristics of the patients, using a commercial machine (Aplio CV; Toshiba Medical Systems Corporation; Tochigi-Ken, Japan) and a 2,5 MHz transducer, as described previously. 15 Measurements of LV diameters and interventricular septum (IVS) and posterior wall (PW) thickness were obtained under 2-dimensional cross-sectional control, with the patient in the partial left decubitus position. LV mass index (LVMI) was calculated by the Penn Convention formula and normalized for body height with a cutoff value of 50 g/m 2.7 for men and 47 g/m 2.7 for women used to define presence of LV hypertrophy. 16 LV systolic function was estimated by the ejection fraction and endocardial fractional shortening. Left atrial end-systolic diameter (LAD) was estimated from the parasternal longaxis view. LV diastolic function was evaluated by pulsed Doppler recordings that were obtained from apical 4-chamber scans at the level of mitral valve tips at end-expiration. Early-(E) and late-wave (A) diastolic velocities, their ratio (E/A), and the E wave deceleration time (DT) were measured. LV diastolic dysfunction was defined by transmitral inflow pattern according to consensus statements 17 TDI was also performed in all patients. This technique assesses the high-amplitude, low-velocity signals of myocardial tissue motion that identify the early diastolic relaxation rate and represent the relaxation velocity during the early active phases of diastole. Under physiological conditions, measurements obtained at TDI are less sensitive to preload than standard transmitral flowrate profiles. 18 Early-diastolic and late-diastolic myocardial velocities of septal and lateral myocardial portions at the level of mitral valve annulus were measured, and the mean values (Em and Am) were calculated on 3 consecutive cardiac cycles together with the average Em/Am ratios. 18 Diastolic dysfunction was defined according to consensus statements 19 on the basis of velocites lower than the age-specific cutoff values (Em <10 cm/sec in patients aged <55 years, <9 cm/sec in patients aged 55-65 years, and <8 cm/sec in patients aged >65 years). 20 
Statistical analysis
Sample size was calculated to provide a statistical power >90% in the detection of a 25% difference in LVMI and variables of diastolic function between patients with normal glucose or IFG/IGT with a probability of <5%. All values are expressed as means ± SDs. Variables with skewed distribution were analyzed after logarithmic transformation. Student t test was used for comparison between 2 groups. Pearson χ 2 test was used to compare frequency distributions. All comparisons were adjusted for covariables. The relationship between continuously distributed variables was examined by linear regression analysis, and the correlation was expressed by Pearson correlation coefficient. Stepwise multiple regression analysis was used to ascertain which variables were independently associated. Two-tailed probability values of <5% were considered to indicate statistical significance.
RESULTS
Clinical characteristics, parameters of glucose metabolism, and echocardiographic variables of the study patients are listed in Table 1 . IFG was present in 12 patients (11%), IGT in 24 patients (23%), and both IFG and IGT in 5 (5%) patients. No differences in age, sex, BMI, blood pressure levels, and duration of hypertension were observed between patients with normal glucose and IFG/IGT. Average values of plasma insulin and HOMA index were higher (by 15% and 28%, respectively) in patients with IFG/IGT than patients with normal glucose, but statistical significance was not reached because of data dispersion. At ECG, LV hypertrophy and strain pattern of the S-T segment were detected in 15% (11 of 73) and 5% (4 of 73), respectively, of patients with normal glucose and 29% (9 of 31; P = 0.02) and 23% (7 of 31; P = 0.04) of patients with IFG/IGT. LVMI, prevalence of echographic LV hypertrophy, relative wall thickness (RWT), LV systolic function, and E/A ratio did not differ significantly between the groups, but patients with IFG/IGT had significantly greater LAD and significantly lower Em and Em/Am than patients with normal glucose. In hypertensive Data are presented as mean ± SD unless otherwise noted. Comparisons between normal fasting and postload plasma glucose (NG) and impaired fasting glucose/impaired glucose tolerance (IFG/IGT) were done by the Student t test after log transformation for variables with skewed distribution. To convert to international units, multiply glucose by 0.05551 (mmol/L), insulin by 7.175 (pmol/L), and C-peptide by 3.021 (nmol/L).
Abbreviations: A, late-wave transmitral diastolic velocity; Am, late-diastolic velocity of septal and lateral myocardial portions at tissue Doppler imaging; BMI, body mass index; BP, blood pressure; DT, E-wave deceleration time; E, early-wave transmitral diastolic velocity; EF, ejection fraction; Em, early-diastolic velocity of septal and lateral myocardial portions at tissue Doppler imaging; G-AUC, area under the curve for plasma glucose after oral glucose load; HOMA, homeostatic model assessment; I-AUC, area under the curve for plasma insulin after oral glucose load; LAD, left atrial diameter; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; RWT, relative wall thickness. patients with IFG/IGT, the age-adjusted prevalence of impaired LV diastolic function as assessed by TDI was significantly greater than in patients with normal plasma glucose, whereas differences were not significant when diastolic dysfunction was assessed by conventional echocardiography (Figure 1) . The percentage of patients who had been previously treated among those with normal glucose or IGF/IGT was 67% (49 of 73) and 65% (20 of 31), respectively, and did not differ between the groups. Table 2 summarizes the clinical, metabolic, and echocardiographic variables of hypertensive patients according to absence/presence of LV diastolic dysfunction as assessed by conventional echocardiography or TDI, respectively. Diastolic dysfunction based on transmitral flow on conventional echocardiography was found in 32 (31%) patients and in 46 (44%) patients on TDI. In all these patients, the pattern of diastolic dysfunction was abnormal relaxation, whereas no pseudo-normal or restrictive filling patterns were found. Hypertensive patients with LV diastolic dysfunction as detected by TDI were older, were more frequently males, and had a greater BMI, systolic blood pressure, fasting and post-oral load plasma glucose, fasting insulin, HOMA index, LVMI, and LAD than patients with a preserved diastolic function (Table 2) . No associations of glucose metabolism variables with other markers of diastolic impairment as detected by conventional echocardiography were observed, and no differences in former use and types of antihypertensive agents were detected between the groups.
Univariable linear regression analysis (Table 3) showed that the E/A ratio and E-wave DT were directly and significantly related with age and fasting plasma glucose. LAD and variables of diastolic function measured at TDI were significantly related with age, BMI, LVMI, RWT, and fasting and post-oral load plasma glucose (Figure 2 ), whereas only LAD had a weak correlation with the HOMA index. Relationships of variables of LV diastolic function with glucose metabolism parameters were further analyzed in a multivariable stepwise regression model that included age, sex, BMI, systolic blood pressure, duration of hypertension, previous antihypertensive drug use, and LVMI or RWT as potential confounders. Analysis showed that Em was independently related with age (β = −0.479; P < 0.001), LVMI (β = −0.281; P = 0.003), and fasting plasma glucose (β = −0.288; P < 0.001) but not G-AUC (β = −0.104; P = 0.24), whereas the Em/Am ratio was independently related with age (β = −0.57; P < 0.001) and both fasting (β = −0.282; P = 0.001) and post−oral load (β = −0.168; P = 0.048) plasma glucose levels. Em was also independently related with RWT (β = −0.296; P < 0.001), and inclusion of RWT in the multivariable analysis did not affect the significant and independent relationship between Em and fasting plasma glucose (β = −0.254; P = 0.002). The Em/Am ratio was not independently related with RWT.
DISCUSSIOn
This study shows that in nondiabetic hypertensive patients without evidence of clinically relevant cardiovascular complications IFG and IGT are associated with increased prevalence of ECG strain pattern of the S-T segment and LV diastolic dysfunction as assessed by cardiac TDI. Variables obtained at TDI detect early changes in LV diastolic function and are significantly related with elevated fasting plasma glucose and increased plasma glucose response to an oral glucose load, but not with insulin sensitivity. The relationship of plasma glucose levels with variables obtained at TDI is independent of major known factors affecting diastolic function such as age, being overweight, blood pressure levels, and LVMI. These findings support the view that LV functional changes that might anticipate clinically overt diastolic heart failure are more frequent in hypertensive patients with abnormal plasma glucose levels even in the absence of diabetes. To our knowledge, this is the first study to demonstrate that nondiabetic fasting and postload hyperglycemia is associated with increased prevalence of electrocardiographic LV strain and evidence of LV diastolic dysfunction at TDI, but not conventional echocardiography, in patients with uncomplicated hypertension.
Diabetic cardiomyopathy is a condition that comprises structural and functional abnormalities that are found in the myocardium of diabetic patients without coronary artery disease. 21 These changes in diabetic hearts result from a variety of mechanisms that are triggered by persistent hyperglycemia and/or decreased cell sensitivity to insulin. Although changes in LV mass and geometry found in diabetics have been almost unanimously ascribed to decreased sensitivity to insulin, 22 the relative impact of fasting or postprandial plasma glucose and insulin levels and insulin resistance on LV diastolic dysfunction has not been fully elucidated. The association of abnormalities of glucose metabolism with changes in LV diastolic function was reported in Data are presented as mean ± SD unless otherwise noted. Comparisons between normal fasting and postload plasma glucose (NG) and impaired fasting glucose/impaired glucose tolerance (IFG/IGT) were done by the Student t test after log transformation for variables with skewed distribution. To convert to international units, multiply glucose by 0.05551 (mmol/L), insulin by 7.175 (pmol/L), and C-peptide by 3.021 (nmol/L).
Abbreviations: A, late-wave transmitral diastolic velocity; Am, late-diastolic velocity of septal and lateral myocardial portions at tissue Doppler imaging; BMI, body mass index; BP, blood pressure; DT, E-wave deceleration time; E, early-wave transmitral diastolic velocity; EF, ejection fraction; Em, early-diastolic velocity of septal and lateral myocardial portions at tissue Doppler imaging; G-AUC, area under the curve for plasma glucose after oral glucose load; HOMA, homeostatic model assessment; I-AUC, area under the curve for plasma insulin after oral glucose load; LAD, left atrial diameter; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; RWT, relative wall thickness. cross-sectional studies that were conducted in the general population 23, 24 and in groups of patients with type 1 25 or type 2 26,27 diabetes and obesity. 28 These studies reported significant relationships of LV diastolic dysfunction with post-oral load plasma glucose, 23 glycated hemoglobin, 23, 25 plasma insulin, 23, 28 and HOMA index. 26 In the Hoorn Study, longitudinal analysis of 394 patients with preserved LV systolic and diastolic function demonstrated that subjects with type 2 diabetes were more likely to develop LV diastolic dysfunction after 8 years. 29 The association between changes in glucose metabolism and LV diastolic dysfunction, however, was not confirmed in another study on type 2 diabetics, 8 and also intervention studies with insulin or oral glucoselowering agents 30, 31 could not show any benefit of metabolic control on LV diastolic function. Also, a study that included subjects with isolated IFG did not report any significant difference in variables of LV diastolic function in comparison with healthy subjects. 32 Much of the controversy in the field has been generated by the limited ability of the conventional echocardiographic technique that has been used in the majority of these studies in detecting initial changes in LV diastolic function. Progress in cardiac ultrasound examination has permitted measurement of myocardial relaxation velocities with TDI, a powerful and increasingly available noninvasive technique for assessment of LV diastolic function. 18 In this study, TDI was used to investigate the relationships between LV diastolic properties and plasma glucose levels in nondiabetic hypertensive patients who were selected to focus on the earliest stages of hyperglycemia, including both subjects with IFG and IGT. Previous studies were conducted in hypertensive patients with diabetes and reported, by use of conventional echocardiography, impaired LV diastolic function with significant association of the E/A ratio with post-oral load plasma glucose, 33 but not glycated hemoglobin. 34 The Strong Heart Study investigated the impact of diabetes on LV filling pattern in normotensive and hypertensive patients and reported that diabetes, especially with inadequate glycemic control, was independently associated with abnormal LV relaxation. 35 In this study, the level of impairment of LV ventricular relaxation was comparable with that of patients with hypertension, and the combination of diabetes and hypertension had more severe LV diastolic impairment than patients with either condition alone. More recently, Sciacqua et al. reported that 1-hour postload plasma glucose is associated with LV diastolic dysfunction in hypertensive subjects with normal glucose tolerance, IGT, or type 2 diabetes. 36 Finally, changes in LV diastolic function have been reported in borderline prehypertensive 7 and normotensive subjects 37 in whom TDI variables were found to be associated with abnormal glucose metabolism. The findings of our study indicate for the first time that early changes in plasma glucose levels, including both IFG and IGT, contribute significantly to ECG signs of LV strain and LV diastolic dysfunction of patients with hypertension even before overt diabetes ensues. Also and most important, multivariable analysis with correction for severity and duration of hypertensive disease suggests that the contribution of elevated plasma glucose to LV diastolic dysfunction is independent of high blood pressure and other possible confounders. Notably, in our study diastolic dysfunction could be demonstrated in patients with hypertension and nondiabetic hyperglycemia only by use of TDI, whereas among the variables measured by conventional echocardiography, only LAD differed significantly between the groups, supporting the importance of this variable as a measure of diastolic dysfunction. 38 A variety of cellular mechanisms could possibly account for the relationship between elevated plasma glucose and early mechanical changes of the LV myocardium as those detected in our patients. 39 These mechanisms include abnormal calcium handling in cardiomyocytes leading to impaired excitation-contraction coupling and diastolic relaxation, downregulation of matrix metalloproteinases and upregulation of tissue inhibitors of metalloproteinases leading to changes in extracellular matrix composition, increase in advanced glycation end products promoting type III collagen crosslinks, and endothelial cell dysfunction with microvascular damage and focal ischemia. Also, elevated glucose levels might be associated with arterial stiffening or a proinflammatory state that might contribute to LV diastolic dysfunction.
Some potential limitations of this study should be discussed. First, the use of a patient sample from university clinic might limit the possibility to generalize conclusions to the general population because of a possible bias in the referral of patients to the source of care. Second, the crosssectional design does not permit us to establish a causal relationship between early changes in plasma glucose levels and LV diastolic dysfunction, although the strength and independence of the relationship reported in the study would suggest so. Third, although the study patients had normal exercise tolerance and no evidence of ischemic heart disease on ECG and echocardiography, presence of subtle coronary heart disease could not be excluded. Last, inclusion of a fraction of hypertensive patients who were not treatment naive might have introduced a possible confounder by affecting some of the cardiac and metabolic variables under study. However, no significant differences in these variables were detected among hypertensive patients that were treated with different types of antihypertensive agents.
In conclusion, this study demonstrates that initial changes in fasting and postload plasma glucose levels are associated with more severe LV diastolic impairment in hypertensive patients, suggesting that even in the absence of overt diabetes, hyperglycemia might increase the risk of diastolic heart failure. This observation has important implications for the identification of subclinical cardiac damage and management of hypertensive patients and supports the opportunity to include assessment of fasting and postload plasma glucose levels in the diagnostic work-up of these patients. Timely intervention on lifestyle or with drugs that correct IFG and IGT might be beneficial in reducing the incidence of LV diastolic impairment and diastolic heart failure in hypertensive patients. These possible benefits will have to be tested in future studies.
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